The use of natalizumab for multiple sclerosis
Rachel Brandstadter, Ilana Katz Sand Department of Neurology, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte t...
Enregistré dans:
Auteurs principaux: | Brandstadter R, Katz Sand I |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/57556eede1514bf2982d42266f37def7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
par: Clara G. Chisari, et autres
Publié: (2021) -
Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review
par: Abril Oliva Ramirez, et autres
Publié: (2021) -
The hospital anxiety and depression scale, in patients with multiple sclerosis
par: Pais-Ribeiro JL, et autres
Publié: (2018) -
The role of microglia in multiple sclerosis
par: Luo C, et autres
Publié: (2017) -
Impact of Andropause on Multiple Sclerosis
par: Maria C. Ysrraelit, et autres
Publié: (2021)